Bill signed by Abbott authorizes psychedelic research, specifically ibogaine, to progress through clinical trials.
Sign up for TPR Today, Texas Public Radio's newsletter, that delivers our top stories straight to your inbox every morning.
In a groundbreaking move, Governor Greg Abbott recently signed Senate Bill 2308 into law, allocating a staggering $50 million for an unprecedented psychedelic research project. This initiative, hailed as the largest state-funded psychedelic research endeavor ever, focuses on advancing ibogaine through FDA-approved clinical trials for various health challenges, including opioid use disorders and other neurological and mental health conditions.
Advocates celebrate this legislation as a pioneering step in the field of psychedelic research. As part of a public-private partnership, private investments—including those from a drug developer—will match the state's funding. In case ibogaine is approved by the FDA, Texas stands to gain a significant portion of the revenue generated from the drug development process.
"Home to more veterans than any other state in the U.S., Texas is now a beacon of hope for those who struggle with conditions like depression, PTSD, and opioid use disorder," explains Abbott. "A therapy that shows immense promise for treating these complications is ibogaine."
Between 1999 and 2022, a heart-wrenching 727,000 lives were lost to opioid overdoses in the U.S. People living in the U.S. who haven't found relief with conventional treatments often seek out ibogaine and other psychedelic therapies abroad, in countries like Mexico, where the treatments are legal or unregulated.
Ibogaine, a psychoactive compound derived from the iboga shrub native to Central West Africa, is classified as a Schedule I drug and is illegal to use or prescribe in the U.S. Nevertheless, it has been an integral part of healing traditions in other countries for centuries.
Former Texas Governor Rick Perry, a staunch advocate of ibogaine legislation, witnessed its transformative effects firsthand with veterans who successfully treated their substance use disorders, PTSD, anxiety, and traumatic brain injuries through ibogaine therapy.
"This work I'm engaged in is the most significant of my career—and I'll dedicate the rest of my life to ensure ibogaine receives the attention and research it deserves," Perry asserts.
Countless U.S. combat veterans endorse the legislation, including Navy SEAL veteran Marcus Luttrell, a Navy Cross and Purple Heart recipient. During a 2005 combat mission in Afghanistan, Luttrell sustained significant physical injuries. "When I was injured, I was introduced to opioids," Luttrell recalls. "After taking ibogaine, I not only stopped drinking, but I no longer craved opioids. The desire simply vanished."
Anecdotal evidence suggests that ibogaine therapy may effectively treat a range of mental health conditions. In April, academic neurosurgeon Achal Singh Achrol testified at the Texas House Committee on Public Health regarding ibogaine's potential benefits.
Achrol shared findings from an observational study at Stanford University led by researchers, involving 30 special operations veterans who independently arranged ibogaine therapy in Mexico to manage their PTSD, anxiety, and depression. "The vast majority of special operations veterans who participated in the study were within the normal range following treatment," Achrol outlined.
The safety of patients undergoing ibogaine therapy is paramount, as the substance carries cardiac risks. Patients consult with clinicians before receiving ibogaine to discuss potential hazards and prepare. Post-treatment, they also meet with healthcare professionals to process their experience and incorporate its lessons into their healing process.
This initiative places Texas at the vanguard of cutting-edge mental health and addiction treatment research, with implications that could potentially reshape national policy and patient care. Other states are already exploring ways to replicate or collaborate with Texas' trailblazing model for psychedelic research.
Be part of the movement; sign up for TPR Today today to stay informed about the latest happenings in Texas' groundbreaking psychedelic research initiative.
[1] Enrichment Data:- Funding Amount: $50 million (largest in history for psychedelic research)- Psychedelic Substance: Ibogaine- Target Conditions: Opioid use disorder, PTSD, depression, other mental health conditions- Research Structure: State-backed consortium (universities, hospitals, drug developers)- State Stake: 20–25% in developed drugs; 25% to veterans’ programs- Regulatory Goal: FDA approval for prescription use
This initiative positions Texas as a pioneer in innovative mental health and addiction treatment research, with far-reaching implications for national policy and patient care.
- The $50 million funding for the psychedelic research project in Texas, aimed at advancing ibogaine through FDA-approved clinical trials, marks the largest state-funded psychedelic research endeavor ever.
- This initiative targets various health challenges, such as opioid use disorders and other neurological and mental health conditions, underscoring its significance in the field of health-and-wellness and mental-health.
- Advocates laud the legislation as a pioneering step in the field of psychedelic research, as it opens doors for potential therapies-and-treatments for chronic-diseases like addiction and neurological-disorders.
- With ibogaine therapy potentially showing effectiveness for treating a range of mental health conditions, the initiative could reshape national policy and patient care in the medical-conditions sector.
- The initiative could generate substantial revenue for Texas once ibogaine is approved by the FDA, as the state stands to gain a significant portion of the revenue generated from the drug development process.
- Politics and general-news outlets may cover the state's trailblazing model for psychedelic research, given its impact on the health-and-wellness, mental-health, and science sectors. Sign up for TPR Today to stay updated on the latest happenings in Texas' groundbreaking psychedelic research initiative.
